Investigation of Freeze/Thaw-Related Quality Attributes of a Liquid Biopharmaceutical Formulation: The Role of Saccharide Excipients

References

1. 1.↵
   1. Rathore N.,
   2. Rajan R. S.

   Current perspectives on stability of protein drug products during formulation, fill and finish operations. Biotechnol. Prog. 2008, 24 (3), 504–514.

   OpenUrlPubMed
2. 2.↵
   1. Shire S. J.

   Formulation and manufacturability of biologics. Curr. Opin. Biotechnol. 2009, 20 (6), 708–714.

   OpenUrl
3. 3.↵
   1. Carpenter J. F.,
   2. Manning M. C.

   1. Chang B. S.,
   2. Hershenson S.

   Practical Approaches to Protein Formulation Development. In Rational Design of Stable Protein Formulations Theory and Practice, Carpenter J. F., Manning M. C. Eds.; Plenum Press: New York, 2002; pp 1–25.
4. 4.↵
   1. Frokjaer S.,
   2. Hovgaard L.

   1. Akers M. J.,
   2. Defelippis M. R.

   Peptides and Proteins as Parenteral Solutions. In Pharmaceutical Formulation Development of Peptides and Proteins, Frokjaer S., Hovgaard L. Eds.; Taylor and Francis Ltd.: London, 2000; pp 145–177.
5. 5.↵
   1. Schneider J. J.

   A study of the osmolality and pH of subcutaneous drug infusion solutions. Australian Journal of Hospital Pharmacy 1997, 27, 29–31.

   OpenUrl
6. 6.↵
   1. Katdare A,
   2. Chaubal M. V.

   1. Gokarn Y. R.,
   2. Kosky A.,
   3. Kras E.,
   4. McAuley A.,
   5. Remmele R. L. J.

   Excipients for Protein Drugs. In Excipient Development for Pharmaceutical, Biotechnology, and Drug Delivery Systems, Katdare A, Chaubal M. V. Eds.; Taylor & Francis Group, LLC: New York, 2006; pp 291–306.
7. 7.↵
   1. Fesinmeyer R. M.,
   2. Hogan S.,
   3. Saluja A.,
   4. Brych S. R.,
   5. Kras E.,
   6. Narhi L. O.,
   7. Brems D. N.,
   8. Gokarn Y. R.

   Effect of ions on agitation- and temperature-induced aggregation reactions of antibodies. Pharm. Res. 2009, 26 (4), 903–913.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Carpenter J. F.,
   2. Pikal M. J.,
   3. Chang B. S.,
   4. Randolph T. W.

   Rational design of stable lyophilized protein formulations: Some practical advice. Pharm. Res. 1997, 14 (8), 969–975.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Shamblin S. L.,
   2. Huang E. Y.,
   3. Zografi G.

   The effects of co-lyophilized polymeric additives on the glass transition temperature and crystallization of amorphous sucrose. Journal of Thermal Analysis 1996, 47 (5), 1567–1579.

   OpenUrl
10. 10.↵
    1. Hancock B. C.,
    2. Shamblin S. L.

    Molecular mobility of amorphous pharmaceuticals determined using differential scanning calorimetry. Thermochimica Acta 2001, 380 (2), 95–107.

    OpenUrl
11. 11.↵
    1. Heller M. C.,
    2. Carpenter J. F.,
    3. Randolph T. W.

    Protein formulation and lyophilization cycle design: Prevention of damage due to freeze-concentration induced phase separation. Biotechnol. Bioeng. 1999, 63 (2), 166–174.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Izutsu K. I.,
    2. Yoshioka S.,
    3. Kojima S.,
    4. Randolph T. W.,
    5. Carpenter J. F.

    Effects of sugars and polymers on crystallization of poly(ethylene glycol) in frozen solutions: Phase separation between incompatible polymers. Pharm. Res. 1996, 13 (9), 1393–1400.

    OpenUrlPubMed
13. 13.↵
    1. Izutsu K. I.,
    2. Kojima S.

    Excipient crystallinity and its protein-structure-stabilizing effect during freeze-drying. J. Pharm. Pharmacol. 2002, 54 (8), 1033–1039.

    OpenUrlPubMed
14. 14.↵
    1. Her L. M.,
    2. Nail S. L.

    Measurement of glass transition temperatures of freeze-concentrated solutes by differential scanning calorimetry. Pharm. Res. 1994, 11 (1) 54–59.

    OpenUrlPubMed
15. 15.↵
    1. Izutsu K. I.,
    2. Yoshioka S.,
    3. Terao T.

    Effect of mannitol crystallinity on the stabilization of enzymes during freeze-drying. Chem. Pharm. Bull. (Tokyo) 1994, 42 (1), 5–8.

    OpenUrlPubMed
16. 16.↵
    1. Yalkowsky S. H.

    Solubility and Solubilization in Aqueous Media. Oxford University Press: New York, 1999.
17. 17.↵
    1. Webb S. D.,
    2. Webb J. N.,
    3. Hughes T. G.,
    4. Sesin D. F.,
    5. Kincaid A. C.

    Freezing bulk-scale biopharmaceuticals using common techniques—and the magnitude of freeze-concentration. BioPharm 2002,15 (5), 22–34.

    OpenUrl
18. 18.↵
    1. Her L. M.,
    2. Deras M.,
    3. Nail S. L.

    Electrolyte-induced changes in glass transition temperatures of freeze-concentrated solutes. Pharm. Res. 1995, 12 (5), 768–772.

    OpenUrlPubMed
19. 19.↵
    1. Zhou R.,
    2. Schlam R. F.,
    3. Yin S.,
    4. Gandhi R. B.,
    5. Adams M. L.

    Scale considerations for selection of saccharide excipients for liquid formulations. J. Pharm. Sci. 2011, 100 (4), 1605–1606.

    OpenUrl
20. 20.↵
    1. Piedmonte D. M.,
    2. Summers C.,
    3. McAuley A.,
    4. Karamujic L.,
    5. Ratnaswamy G.

    Sorbitol crystallization can lead to protein aggregation in frozen protein formulations. Pharm. Res. 2007, 24 (1), 136–146.

    OpenUrlPubMed
21. 21.↵
    1. Williams N. A.,
    2. Lee Y.,
    3. Polli G. P.,
    4. Jennings T. A.

    The effects of cooling rate on solid phase transitions and associated vial breakage occurring in frozen mannitol solutions. PDA J. Pharm. Sci. Technol. 1986, 40 (4), 135–141.

    OpenUrl
22. 22.↵
    1. Johnson R. E.,
    2. Kirchhoff C. F.,
    3. Gaud H. T.

    Mannitol-sucrose mixtures—versatile formulations for protein lyophilization. J. Pharm. Sci. 2002, 91 (4), 914–922.

    OpenUrlPubMed
23. 23.↵
    1. Cavatur R. K.,
    2. Vemuri N. M.,
    3. Pyne A.,
    4. Chrzan Z.,
    5. Toledo-Velasquez D.,
    6. Suryanarayanan R.

    Crystallization behavior of mannitol in frozen aqueous solutions. Pharm. Res. 2002, 19 (6), 894–900.

    OpenUrlCrossRefPubMedWeb of Science
24. 24.↵
    1. Kolhe P.,
    2. Amend E.,
    3. Singh S. K.

    Impact of freezing on pH of buffered solutions and consequences for monoclonal antibody aggregation. Biotechnol. Prog. 2010, 26 (3), 727–733.

    OpenUrlPubMed
25. 25.↵
    1. Kolhe P.,
    2. Holding E.,
    3. Lary A.,
    4. Chico S.,
    5. Singh S. K.

    Large-scale freezing of biologics: Understanding protein and solute concentration changes in a cryovessel—Part 2. BioPharm Int. 2010, 23 (7), 40–49.

    OpenUrl
26. 26.↵
    1. Kolhe P.,
    2. Holding E.,
    3. Lary A.,
    4. Chico S.,
    5. Singh S. K.

    Large-scale freezing of biologics: Understanding protein and solute concentration changes in a cryovessel—Part I. BioPharm Int. 2010, 23 (6), 53–60.

    OpenUrl
27. 27.↵
    1. Singh S. K.,
    2. Kolhe P.,
    3. Wang W.,
    4. Nema S.

    Large-scale freezing of biologics: a practitioner's review, Part 2: Practical advice. BioProcess International 2009, 7 (10), 34–42.

    OpenUrl
28. 28.↵
    1. Singh S. K.,
    2. Kolhe P.,
    3. Wang W.,
    4. Nema S.

    Large-scale freezing of biologics: a practitioner's review, Part 1: Fundamental aspects. BioProcess International 2009, 7 (9), 32–44.

    OpenUrl
29. 29.↵
    1. Singh S. K.,
    2. Rathore N.,
    3. McAuley A.,
    4. Rathore A. S.

    Best practices for the formulation and manufacturing of biotech drug products. BioPharm Int. 2009, 22 (6), 32–34 and 38–48.

    OpenUrl
30. 30.↵
    1. Maity H.,
    2. Karkaria C.,
    3. Davagnino J.

    Mapping of solution components, pH changes, protein stability and the elimination of protein precipitation during freeze-thawing of fibroblast growth factor 20. Int. J. Pharm. 2009, 378 (1–2), 122–135.

    OpenUrlPubMed
31. 31.↵
    1. Kolhe P.,
    2. Badkar A.

    Protein and solute distribution in drug substance containers during frozen storage and post-thawing: A tool to understand and define freezing-thawing parameters in biotechnology process development. Biotechnol. Prog. 2011, 27 (2), 494–504.

    OpenUrlPubMed
32. 32.↵
    1. Rowe R. C.,
    2. Sheskey P. J.,
    3. Quinn M. E.

    Hand Book of Pharmaceutical Excipients, 6th ed.; Pharmaceutical Press: London, 2009.
33. 33.↵
    1. Frokjaer S.,
    2. Otzen D. E.

    Protein drug stability: a formulation challenge. Nat. Rev. Drug Discov. 2005, 4 (4), 298–306.

    OpenUrlCrossRefPubMedWeb of Science
34. 34.↵
    1. Williams N. A.,
    2. Dean T.

    Vial breakage by frozen mannitol solutions: correlation with thermal characteristics and effect of stereoisomerism, additives, and vial configuration. PDA J. Pharm. Sci. Technol. 1991, 45 (2), 94–100.

    OpenUrlAbstract/FREE Full Text
35. 35.↵
    1. Williams N. A.,
    2. Guglielmo J.

    Thermal mechanical analysis of frozen solutions of mannitol and some related stereoisomers: evidence of expansion during warming and correlation with vial breakage during lyophilization. J. Parenter. Sci. Technol. 1993, 47 (3), 119–123.

    OpenUrlPubMed
36. 36.↵
    1. Jiang G.,
    2. Akers M.,
    3. Jain M.,
    4. Guo J.,
    5. Distler A.,
    6. Swift R.,
    7. Wadhwa M. V.,
    8. Jameel F.,
    9. Patro S.,
    10. Freund E.

    Mechanistic studies of glass vial breakage for frozen formulations. I. Vial breakage caused by crystallizable excipient mannitol. PDA J. Pharm. Sci. Technol. 2007, 61 (6), 441–451.

    OpenUrlAbstract/FREE Full Text
37. 37.↵
    1. Jiang G.,
    2. Akers M.,
    3. Jain M.,
    4. Guo J.,
    5. Distler A.,
    6. Swift R.,
    7. Wadhwa M. V.,
    8. Jameel F.,
    9. Patro S.,
    10. Freund E.

    Mechanistic studies of glass vial breakage for frozen formulations. II. Vial breakage caused by amorphous protein formulations. PDA J. Pharm. Sci. Technol. 2007, 61 (6), 452–460.

    OpenUrlAbstract/FREE Full Text